News

The company’s lead product candidate, enobosarm, is also being evaluated in a separate Phase II clinical trial to treat estrogen receptor positive (ER+), AR+ breast cancer. The open-label,

AmerisourceBergen president and CEO Steven Collis said: "The acquisition of PharMEDium strengthens our core business and meaningfully expands our innovative service offerings for health systems. "PharMEDium is a

The FDA has determined MPI’s Hydroxyprogesterone Caproate Injection USP, 250 mg/ mL (1.25 g/5 mL vials) to be bioequivalent and, therefore, therapeutically equivalent to Delalutin Injection, 250 mg/mL

The trial is a randomized, double blind, active control, multi-center, global study in patients with chronic plaque psoriasis to compare the safety, efficacy and immunogenicity of M923 with

OTO-311 is a sustained-exposure formulation of potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. The approval has been granted to commence a Phase I dose escalation clinical safety

Quinsair is an inhaled formulation of levofloxacin, which already received approval in the European Union and Canada. It is used to manage chronic pulmonary infections due to Pseudomonas

SEC alleged that the company’s JV violated the Foreign Corrupt Practices Act (FCPA) and reaped over $11m in profits from this violation. According to the SEC’s order instituting

With the approval, the company now intends to begin the PRTX-100-203 trial at several sites in France with patient enrollment expected to start by this year end. Furthermore,

The first half of the prize has been awarded jointly to Ireland born William Campbell and Japanese scientist Satoshi Omura by the Nobel Assembly at Karolinska Institutet for